{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:58:04Z","timestamp":1791140284597,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K02603"],"award-info":[{"award-number":["JP25K02603"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K24259"],"award-info":[{"award-number":["JP23K24259"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Parkinson\u2019s and Alzheimer\u2019s Disease Dimensional Neuroimaging Initiative","award":["the Parkinson\u2019s and Alzheimer\u2019s Disease Dimensional Neuroimaging Initiative (PADNI)"],"award-info":[{"award-number":["the Parkinson\u2019s and Alzheimer\u2019s Disease Dimensional Neuroimaging Initiative (PADNI)"]}]},{"name":"Clinical Research Program from Nihon Medi-Physics Co., Ltd.","award":["Clinical Research Program from Nihon Medi-Physics Co., Ltd."],"award-info":[{"award-number":["Clinical Research Program from Nihon Medi-Physics Co., Ltd."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      We aimed to compare visual and quantitative assessments between PET\/CT at 90\u00a0min and sequential PET\/MRI at approximately 120\u00a0min after injection of\n                      <jats:sup>18<\/jats:sup>\n                      F-flutemetamol, and to investigate factors affecting differences in standardized uptake value ratio (SUVr) and Centiloid scale.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Eighty-three participants underwent both PET\/CT and sequential PET\/MRI. Two nuclear medicine physicians performed visual interpretations. SUVr was calculated using four reference regions\u2014pons, whole cerebellum, cerebellar gray matter (CGM), and whole cerebellum and brainstem\u2014and compared between PET\/CT and PET\/MRI. Centiloid Scale was also compared between PET\/CT and PET\/MRI. Subgroup analyses were conducted based on Centiloid scale. Associations between scan interval, age, and amyloid burden were evaluated using stepwise regression. Cerebrospinal fluid (CSF) biomarkers were compared with imaging findings in 52 participants. Additionally, six participants underwent dynamic PET\/MRI at 0, 60, 90, and 120\u00a0min post-injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Visual interpretation showed high agreement between PET\/CT and PET\/MRI (\u03ba\u2009=\u20090.97), and 98% concordance with CSF findings. SUVr and Centiloid scale demonstrated a strong intraclass correlation coefficient of 0.96\u20130.98. However, SUVr and Centiloid scale were significantly higher from PET\/CT than from PET\/MRI, except for SUVr using CGM. Age and Centiloid scale were significant predictors of modality differences. Scan interval was also significant when CGM was used as the reference region. Dynamic PET\/MRI revealed time-dependent increases in Centiloid scale among amyloid-positive participants.<\/jats:p>\n                    <jats:p>\n                      High concordance in visual and quantitative assessments was seen for\n                      <jats:sup>18<\/jats:sup>\n                      F-flutemetamol PET\/CT (90\u00a0min) and subsequent PET\/MRI (120\u00a0min). While diagnostic agreement was preserved, quantitative values were influenced by amyloid burden, age, and scan timing. These findings suggest a need for careful consideration when interpreting quantitative metrics across different imaging modalities and time points.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-025-01915-1","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T05:33:32Z","timestamp":1765344812000},"page":"685-697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sequential scans of 18F-flutemetamol PET using PET\/CT and PET\/MRI: influence of amyloid burden, scan interval, and age"],"prefix":"10.1007","volume":"44","author":[{"given":"Shin","family":"Morooka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1982-3168","authenticated-orcid":false,"given":"Yasutaka","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachi","family":"Okuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Mitsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Itagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiho","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kuzuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hanakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukatsu","family":"Sawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"1915_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u20136.","journal-title":"Science"},{"key":"1915_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"1915_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"1915_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"1915_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287\u201394.","journal-title":"JAMA Neurol"},{"key":"1915_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669\u201378.","journal-title":"Lancet Neurol"},{"key":"1915_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275\u201383.","journal-title":"JAMA"},{"issue":"8","key":"1915_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964\u201374. https:\/\/doi.org\/10.1016\/j.jalz.2015.02.004.","journal-title":"Alzheimers Dement"},{"key":"1915_CR9","doi-asserted-by":"publisher","first-page":"e-1","DOI":"10.1016\/j.jalz.2013.01.002","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the alzheimer\u2019s association. Alzheimers Dement. 2013;9:e-1-16.","journal-title":"Alzheimers Dement"},{"key":"1915_CR10","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvado G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49:3508\u201328.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1915_CR11","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s12149-022-01792-y","volume":"36","author":"H Matsuda","year":"2022","unstructured":"Matsuda H, Okita K, Motoi Y, Mizuno T, Ikeda M, Sanjo N, et al. Clinical impact of amyloid PET using (18)F-florbetapir in patients with cognitive impairment and suspected Alzheimer\u2019s disease: a multicenter study. Ann Nucl Med. 2022;36:1039\u201349.","journal-title":"Ann Nucl Med"},{"key":"1915_CR12","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2967\/jnumed.116.174615","volume":"57","author":"S Minoshima","year":"2016","unstructured":"Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, et al. SNMMI procedure standard\/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med. 2016;57:1316\u201322.","journal-title":"J Nucl Med"},{"key":"1915_CR13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268754","author":"J Arbizu","year":"2024","unstructured":"Arbizu J, Morbelli S, Minoshima S, Barthel H, Kuo P, Van Weehaeghe D, et al. SNMMI procedure standard\/EANM practice guideline for brain [(18)F]FDG PET imaging, version 2.0. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/jnumed.124.268754.","journal-title":"J Nucl Med"},{"key":"1915_CR14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.nicl.2015.10.007","volume":"9","author":"JM Mountz","year":"2015","unstructured":"Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, et al. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer\u2019s subjects. NeuroImage: Clin. 2015;9:592\u20138. https:\/\/doi.org\/10.1016\/j.nicl.2015.10.007.","journal-title":"NeuroImage: Clin"},{"key":"1915_CR15","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00259-015-3067-9","volume":"42","author":"P Payoux","year":"2015","unstructured":"Payoux P, Delrieu J, Gallini A, Adel D, Salabert AS, Hitzel A, et al. Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imaging. 2015;42:1459\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1915_CR16","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.2967\/jnumed.115.156414","volume":"56","author":"C Hosokawa","year":"2015","unstructured":"Hosokawa C, Ishii K, Kimura Y, Hyodo T, Hosono M, Sakaguchi K, et al. Performance of 11C-Pittsburgh Compound B PET binding potential images in the detection of amyloid deposits on equivocal static images. J Nucl Med. 2015;56:1910\u20135.","journal-title":"J Nucl Med"},{"key":"1915_CR17","doi-asserted-by":"publisher","first-page":"578753","DOI":"10.3389\/fneur.2020.578753","volume":"11","author":"H Matsuda","year":"2020","unstructured":"Matsuda H, Ito K, Ishii K, Shimosegawa E, Okazawa H, Mishina M, et al. Quantitative evaluation of (18)F-flutemetamol PET in patients with cognitive impairment and suspected Alzheimer\u2019s disease: a multicenter study. Front Neurol. 2020;11:578753.","journal-title":"Front Neurol"},{"key":"1915_CR18","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251\u20139.","journal-title":"J Nucl Med"},{"key":"1915_CR19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuroimage.2018.03.021","volume":"174","author":"JMG van Bergen","year":"2018","unstructured":"van Bergen JMG, Li X, Quevenco FC, Gietl AF, Treyer V, Meyer R, et al. Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and beta-amyloid as an indicator of cognitive performance at high age. Neuroimage. 2018;174:308\u201316.","journal-title":"Neuroimage"},{"key":"1915_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/0271678X221124656","volume":"43","author":"E Saka","year":"2023","unstructured":"Saka E, Atay LO, Akdemir UO, Yetim E, Balci E, Arsava EM, et al. Cerebral vasomotor reactivity across the continuum of subjective cognitive impairment, amnestic mild cognitive impairment and probable Alzheimer\u2019s dementia: a transcranial Doppler and PET\/MRI study. J Cereb Blood Flow Metab. 2023;43:129\u201337.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1915_CR21","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1093\/brain\/awad077","volume":"146","author":"EM Coomans","year":"2023","unstructured":"Coomans EM, Tomassen J, Ossenkoppele R, Tijms BM, Lorenzini L, Ten Kate M, et al. Genetically identical twin-pair difference models support the amyloid cascade hypothesis. Brain. 2023;146:3735\u201346.","journal-title":"Brain"},{"key":"1915_CR22","doi-asserted-by":"publisher","first-page":"760518","DOI":"10.3389\/fneur.2021.760518","volume":"12","author":"M Garon","year":"2021","unstructured":"Garon M, Weis L, Fiorenzato E, Pistonesi F, Cagnin A, Bertoldo A, et al. Quantification of brain beta-amyloid load in Parkinson\u2019s disease with mild cognitive impairment: a PET\/MRI study. Front Neurol. 2021;12:760518.","journal-title":"Front Neurol"},{"key":"1915_CR23","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s12149-024-01955-z","volume":"38","author":"R Yamakuni","year":"2024","unstructured":"Yamakuni R, Murakami T, Ukon N, Kakamu T, Toda W, Hattori K, et al. Differential centiloid scale normalization techniques: comparison between hybrid PET\/MRI and independently acquired MRI. Ann Nucl Med. 2024;38:835\u201346.","journal-title":"Ann Nucl Med"},{"issue":"13","key":"1915_CR24","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1002\/hbm.25039","volume":"41","author":"H Arabi","year":"2020","unstructured":"Arabi H, Bortolin K, Ginovart N, Garibotto V, Zaidi H. Deep learning-guided joint attenuation and scatter correction in multitracer neuroimaging studies. Hum Brain Mapp. 2020;41(13):3667\u201379. https:\/\/doi.org\/10.1002\/hbm.25039.","journal-title":"Hum Brain Mapp"},{"key":"1915_CR25","doi-asserted-by":"publisher","first-page":"23TR02","DOI":"10.1088\/1361-6560\/abb0f8","volume":"65","author":"C Catana","year":"2020","unstructured":"Catana C. Attenuation correction for human PET\/MRI studies. Phys Med Biol. 2020;65:23TR02.","journal-title":"Phys Med Biol"},{"key":"1915_CR26","doi-asserted-by":"crossref","unstructured":"Lin H, Jiang Q, Yang Y, Huang Q, Zhang Y, Zhang Z, et al. Harmonizing Abeta deposition threshold for (18)F-florbetaben PET imaging: Addressing discrepancies and calibration between PET\/CT and PET\/MRI. Eur J Nucl Med Mol Imaging. 2025.","DOI":"10.1007\/s00259-025-07279-y"},{"key":"1915_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"1915_CR28","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601.","journal-title":"Mov Disord"},{"key":"1915_CR29","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5","author":"Association AP","year":"2013","unstructured":"Association AP. Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association Publishing; 2013."},{"issue":"4","key":"1915_CR30","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, et al. The AHEAD 3-45 study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(4):1227\u201333. https:\/\/doi.org\/10.1002\/alz.12748.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1915_CR31","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ana.25811","volume":"88","author":"DJ Irwin","year":"2020","unstructured":"Irwin DJ, Fedler J, Coffey CS, Caspell-Garcia C, Kang JH, Simuni T, et al. Evolution of Alzheimer\u2019s disease cerebrospinal fluid biomarkers in early Parkinson\u2019s disease. Ann Neurol. 2020;88(3):574\u201387. https:\/\/doi.org\/10.1002\/ana.25811.","journal-title":"Ann Neurol"},{"issue":"4","key":"1915_CR32","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3233\/JPD-212989","volume":"12","author":"S Weinshel","year":"2022","unstructured":"Weinshel S, Irwin DJ, Zhang P, Weintraub D, Shaw LM, Siderowf A, et al. Appropriateness of applying cerebrospinal fluid biomarker cutoffs from Alzheimer\u2019s disease to Parkinson\u2019s disease. J Parkinsons Dis. 2022;12(4):1155\u201367. https:\/\/doi.org\/10.3233\/JPD-212989.","journal-title":"J Parkinsons Dis"},{"key":"1915_CR33","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1093\/brain\/awae303","volume":"147","author":"Y Sakato","year":"2024","unstructured":"Sakato Y, Shima A, Terada Y, Takeda K, Sakamaki-Tsukita H, Nishida A, et al. Delineating three distinct spatiotemporal patterns of brain atrophy in Parkinson\u2019s disease. Brain. 2024;147:3702\u201313.","journal-title":"Brain"},{"issue":"2","key":"1915_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2967\/jnumed.122.264256","volume":"64","author":"C Boccalini","year":"2022","unstructured":"Boccalini C, Peretti DE, Ribaldi F, Scheffler M, Stampacchia S, Tomczyk S, et al. Early-phase (18)F-florbetapir and (18)F-flutemetamol images as proxies of brain metabolism in a memory clinic setting. J Nucl Med. 2022;64(2):266\u201373. https:\/\/doi.org\/10.2967\/jnumed.122.264256.","journal-title":"J Nucl Med"},{"issue":"8","key":"1915_CR35","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1002\/alz.13893","volume":"20","author":"E Johns","year":"2024","unstructured":"Johns E, Vossler HA, Young CB, Carlson ML, Winer JR, Younes K, et al. Florbetaben amyloid PET acquisition time: influence on Centiloids and interpretation. Alzheimers Dement. 2024;20(8):5299\u2013310. https:\/\/doi.org\/10.1002\/alz.13893.","journal-title":"Alzheimers Dement"},{"key":"1915_CR36","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.2967\/jnumed.117.200964","volume":"59","author":"S Bullich","year":"2018","unstructured":"Bullich S, Barthel H, Koglin N, Becker GA, De Santi S, Jovalekic A, et al. Validation of noninvasive tracer kinetic analysis of (18)F-Florbetaben PET using a dual-time-window acquisition protocol. J Nucl Med. 2018;59:1104\u201310.","journal-title":"J Nucl Med"},{"key":"1915_CR37","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","volume":"85","author":"S Palmqvist","year":"2015","unstructured":"Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Alzheimer\u2019s Disease Neuroimaging I, Minthon L, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85:1240\u20139.","journal-title":"Neurology"},{"key":"1915_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00406-023-01701-y","volume":"275","author":"N Guillen","year":"2025","unstructured":"Guillen N, Contador J, Buongiorno M, Alvarez I, Culell N, Alcolea D, et al. Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study. Eur Arch Psychiatry Clin Neurosci. 2025;275:257\u201366.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1915_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cca.2019.02.005","volume":"492","author":"C Bouter","year":"2019","unstructured":"Bouter C, Vogelgsang J, Wiltfang J. Comparison between amyloid-PET and CSF amyloid-beta biomarkers in a clinical cohort with memory deficits. Clin Chim Acta. 2019;492:62\u20138.","journal-title":"Clin Chim Acta"},{"key":"1915_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-022-01003-w","volume":"14","author":"M Amft","year":"2022","unstructured":"Amft M, Ortner M, Eichenlaub U, Goldhardt O, Diehl-Schmid J, Hedderich DM, et al. The cerebrospinal fluid biomarker ratio Abeta42\/40 identifies amyloid positron emission tomography positivity better than Abeta42 alone in a heterogeneous memory clinic cohort. Alzheimers Res Ther. 2022;14:60.","journal-title":"Alzheimers Res Ther"},{"key":"1915_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13195-017-0260-z","volume":"9","author":"F Ben Bouallegue","year":"2017","unstructured":"Ben Bouallegue F, Mariano-Goulart D, Payoux P, Alzheimer\u2019s Disease Neuroimaging I. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer\u2019s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Alzheimers Res Ther. 2017;9:32.","journal-title":"Alzheimers Res Ther"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-025-01915-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:35:26Z","timestamp":1774935326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-025-01915-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1915"],"URL":"https:\/\/doi.org\/10.1007\/s11604-025-01915-1","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Kyoto University Graduate School and Faculty of Medicine, Ethics Committee (May 8, 2020\/C1468).\u201d","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the image (Fig.\u00a0\n                      \n                      ).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}